Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits
Abstract The Food and Drug Administration warned against fluoroquinolone use for conditions with effective alternative agents. An estimated 5.1% of adult ambulatory fluoroquinolone prescriptions were for conditions that did not require antibiotics, and 19.9% were for conditions where fluoroquinolone...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2018-06, Vol.67 (1), p.134-136 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 136 |
|---|---|
| container_issue | 1 |
| container_start_page | 134 |
| container_title | Clinical infectious diseases |
| container_volume | 67 |
| creator | Kabbani, Sarah Hersh, Adam L Shapiro, Daniel J Fleming-Dutra, Katherine E Pavia, Andrew T Hicks, Lauri A |
| description | Abstract
The Food and Drug Administration warned against fluoroquinolone use for conditions with effective alternative agents. An estimated 5.1% of adult ambulatory fluoroquinolone prescriptions were for conditions that did not require antibiotics, and 19.9% were for conditions where fluoroquinolones are not recommended first-line therapy. Unnecessary fluoroquinolone use should be reduced. |
| doi_str_mv | 10.1093/cid/ciy035 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6005119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciy035</oup_id><sourcerecordid>2082631838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-3d24be00acd7c8fab20b04c585c5d55502704165804af7fdaa72cc0a4d3493dd3</originalsourceid><addsrcrecordid>eNp9kUlLBDEQhYMo7hd_gATEi9Ba6SS9XIRhcANhBJdrSCdpzdDTaZO0MP_eyIyiFw-hAvnq1Us9hI4InBOo6YWyOp0lUL6BdgmnZVbwmmymO_AqYxWtdtBeCHMAQirg22gnr2lJi4LtovlsGJyPY2-jNQFHh-8Wg3cfBl93o_PufbS961xv8IM3QXnb2P4V2x7HN4OfU5fR-DHKmHpb5_FEj13Ek0UzdjI6v8RT6Q1-scHGcIC2WtkFc7iu--j5-uppepvdz27uppP7TDFaxIzqnDUGQCpdqqqVTQ4NMMUrrrjmnENeAiMFr4DJtmy1lGWuFEimKaup1nQfXa50h7FZGK1MH73sxODtQvqlcNKKvy-9fROv7kMUAJyQOgmcrAW-_m9CFHM3-j55FjlUeUFJWmmizlaU8i4Eb9qfCQTEVy4i5SJWuST4-LenH_Q7iAScrgA3Dv8JfQLHPpkt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2082631838</pqid></control><display><type>article</type><title>Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Kabbani, Sarah ; Hersh, Adam L ; Shapiro, Daniel J ; Fleming-Dutra, Katherine E ; Pavia, Andrew T ; Hicks, Lauri A</creator><creatorcontrib>Kabbani, Sarah ; Hersh, Adam L ; Shapiro, Daniel J ; Fleming-Dutra, Katherine E ; Pavia, Andrew T ; Hicks, Lauri A</creatorcontrib><description>Abstract
The Food and Drug Administration warned against fluoroquinolone use for conditions with effective alternative agents. An estimated 5.1% of adult ambulatory fluoroquinolone prescriptions were for conditions that did not require antibiotics, and 19.9% were for conditions where fluoroquinolones are not recommended first-line therapy. Unnecessary fluoroquinolone use should be reduced.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciy035</identifier><identifier>PMID: 29373664</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Ambulatory care ; Antibiotics ; Brief Reports ; Emergency medical services ; Fluoroquinolones</subject><ispartof>Clinical infectious diseases, 2018-06, Vol.67 (1), p.134-136</ispartof><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2018. 2018</rights><rights>Copyright Oxford University Press Jul 1, 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-3d24be00acd7c8fab20b04c585c5d55502704165804af7fdaa72cc0a4d3493dd3</citedby><cites>FETCH-LOGICAL-c436t-3d24be00acd7c8fab20b04c585c5d55502704165804af7fdaa72cc0a4d3493dd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29373664$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kabbani, Sarah</creatorcontrib><creatorcontrib>Hersh, Adam L</creatorcontrib><creatorcontrib>Shapiro, Daniel J</creatorcontrib><creatorcontrib>Fleming-Dutra, Katherine E</creatorcontrib><creatorcontrib>Pavia, Andrew T</creatorcontrib><creatorcontrib>Hicks, Lauri A</creatorcontrib><title>Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract
The Food and Drug Administration warned against fluoroquinolone use for conditions with effective alternative agents. An estimated 5.1% of adult ambulatory fluoroquinolone prescriptions were for conditions that did not require antibiotics, and 19.9% were for conditions where fluoroquinolones are not recommended first-line therapy. Unnecessary fluoroquinolone use should be reduced.</description><subject>Ambulatory care</subject><subject>Antibiotics</subject><subject>Brief Reports</subject><subject>Emergency medical services</subject><subject>Fluoroquinolones</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kUlLBDEQhYMo7hd_gATEi9Ba6SS9XIRhcANhBJdrSCdpzdDTaZO0MP_eyIyiFw-hAvnq1Us9hI4InBOo6YWyOp0lUL6BdgmnZVbwmmymO_AqYxWtdtBeCHMAQirg22gnr2lJi4LtovlsGJyPY2-jNQFHh-8Wg3cfBl93o_PufbS961xv8IM3QXnb2P4V2x7HN4OfU5fR-DHKmHpb5_FEj13Ek0UzdjI6v8RT6Q1-scHGcIC2WtkFc7iu--j5-uppepvdz27uppP7TDFaxIzqnDUGQCpdqqqVTQ4NMMUrrrjmnENeAiMFr4DJtmy1lGWuFEimKaup1nQfXa50h7FZGK1MH73sxODtQvqlcNKKvy-9fROv7kMUAJyQOgmcrAW-_m9CFHM3-j55FjlUeUFJWmmizlaU8i4Eb9qfCQTEVy4i5SJWuST4-LenH_Q7iAScrgA3Dv8JfQLHPpkt</recordid><startdate>20180618</startdate><enddate>20180618</enddate><creator>Kabbani, Sarah</creator><creator>Hersh, Adam L</creator><creator>Shapiro, Daniel J</creator><creator>Fleming-Dutra, Katherine E</creator><creator>Pavia, Andrew T</creator><creator>Hicks, Lauri A</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20180618</creationdate><title>Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits</title><author>Kabbani, Sarah ; Hersh, Adam L ; Shapiro, Daniel J ; Fleming-Dutra, Katherine E ; Pavia, Andrew T ; Hicks, Lauri A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-3d24be00acd7c8fab20b04c585c5d55502704165804af7fdaa72cc0a4d3493dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Ambulatory care</topic><topic>Antibiotics</topic><topic>Brief Reports</topic><topic>Emergency medical services</topic><topic>Fluoroquinolones</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kabbani, Sarah</creatorcontrib><creatorcontrib>Hersh, Adam L</creatorcontrib><creatorcontrib>Shapiro, Daniel J</creatorcontrib><creatorcontrib>Fleming-Dutra, Katherine E</creatorcontrib><creatorcontrib>Pavia, Andrew T</creatorcontrib><creatorcontrib>Hicks, Lauri A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kabbani, Sarah</au><au>Hersh, Adam L</au><au>Shapiro, Daniel J</au><au>Fleming-Dutra, Katherine E</au><au>Pavia, Andrew T</au><au>Hicks, Lauri A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2018-06-18</date><risdate>2018</risdate><volume>67</volume><issue>1</issue><spage>134</spage><epage>136</epage><pages>134-136</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Abstract
The Food and Drug Administration warned against fluoroquinolone use for conditions with effective alternative agents. An estimated 5.1% of adult ambulatory fluoroquinolone prescriptions were for conditions that did not require antibiotics, and 19.9% were for conditions where fluoroquinolones are not recommended first-line therapy. Unnecessary fluoroquinolone use should be reduced.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>29373664</pmid><doi>10.1093/cid/ciy035</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2018-06, Vol.67 (1), p.134-136 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6005119 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Ambulatory care Antibiotics Brief Reports Emergency medical services Fluoroquinolones |
| title | Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A14%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Opportunities%20to%20Improve%20Fluoroquinolone%20Prescribing%20in%20the%20United%20States%20for%20Adult%20Ambulatory%20Care%20Visits&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Kabbani,%20Sarah&rft.date=2018-06-18&rft.volume=67&rft.issue=1&rft.spage=134&rft.epage=136&rft.pages=134-136&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciy035&rft_dat=%3Cproquest_pubme%3E2082631838%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2082631838&rft_id=info:pmid/29373664&rft_oup_id=10.1093/cid/ciy035&rfr_iscdi=true |